The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Karen Pollok, Tim Lautenschlaeger, Jiang Bian named to leadership at IU Simon CCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Karen Pollok

Tim Lautenschlaeger

Jiang Bian

Karen Pollok was named associate director of basic science research and Tim Lautenschlaeger was named associate director of clinical research at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center. Jiang Bian also recently began as chief research information officer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Black patients who receive docetaxel for breast cancer experience less peripheral neuropathy than those who receive paclitaxel

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account